Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor

Thrombosis and Haemostasis

Volumn 84, Issue 5, 2000, Pages 858-864

  Friederich, P W ^a   Keller, T T ^a   Biemond, B J ^a   Peters, R J G ^a   Hornberger, W ^a   Buller, H R ^a   Levi, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulants; Coagulation; Rabbits; Thrombin inhibitor; Thrombosis

Indexed keywords

ACTIN; BSF 208791; ECARIN; HIRUDIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; JUGULAR VEIN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; STRUCTURE ACTIVITY RELATION; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0033678017     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614128     Document Type: Article

References (46)

1. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: Initial patency and influence of maintained infusion on reocclusion rate
2. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: A report from the NHLBI thrombolysis in myocardial infarction trial
3. A canine model of coronary artery thrombosis with super-imposed high grade stenosis for the investigation of rethrombosis after thrombolysis
4. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction
5. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
6. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
7. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties
8. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
9. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone
10. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty
11. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
12. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators
13. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
14. Optimal intensity of oral anticoagulant therapy after myocardial infarction
15. A method to determine the optimal intensity of oral anticoagulant therapy
16. A 7-year analysis of haemorrhage in patients on long-term anti-coagulant treatment
17. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage
18. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
19. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group
20. Variations in prothrombin time and international normalized ratio over 24 hours in warfarin-treated patients
21. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo
22. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
23. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers
24. Thrombin inhibition and intracoronary thrombus formation: Effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery
25. High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery
26. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg
27. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model
28. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
29. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group
30. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
31. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method
32. A New Method for Therapeutical Monitoring of Hirudin
33. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment. An evaluation of native blood and plasma assays
34. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity
35. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits
36. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group
37. The duration of oral anticoagulation after deep vein thrombosis. A randomized study
38. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
39. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group
40. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation
41. Bleeding time and bleeding: An analysis of the relationship of the bleeding time test with parameters of surgical bleeding
42. A critical reappraisal of the bleeding time
43. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog
44. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis
45. Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats
46. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery